CCO Oncology Podcast

Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

Episode Summary

In this podcast episode, listen to Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, as they answer questions on managing NF1 and using MEK inhibitors for NF1-associated plexiform neurofibromas.

Episode Notes

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:  

• Whole exome sequencing for diagnosis
• When to treat asymptomatic tumors
• Genetic testing of family members
• Choosing a MEK inhibitor
• Supportive care for acneiform rash
• Other RAS pathway inhibitors

Presenters:

Scott R. Plotkin, MD, PhD
Executive Director
Pappas Center for Neuro-Oncology
Professor of Neurology
Harvard Medical School
Boston, Massachusetts

Brian D. Weiss, MD
Clinical Professor of Pediatrics
Cancer and Blood Diseases Institute Division of Oncology  
Medical Director
Solid Tumor Program
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3AXckHQ